Laurent Décosterd

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


253 publications

Sous presse | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | ...
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al. The Journal of antimicrobial chemotherapy. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_525CE7DE74FD]
 
Imatinib uptake into cells is not mediated by organic cation transporters OCT1, OCT2, or OCT3, but is influenced by extracellular pH.
Blanc Mettral J., Faller N., Cruchon S., Sottas L., Buclin T., Schild L., Choong E., Nahimana A., Decosterd L.A. Drug metabolism letters. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_6F47958A0A5D]
 
Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial.
Braun D.L., Turk T., Tschumi F., Grube C., Hampel B., Depmeier C., Schreiber P.W., Brugger S.D., Greiner M., Steffens D. et al. Clinical infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_91F295C7932F]
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. The Journal of antimicrobial chemotherapy. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_5082024839D9]
 
Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al. British journal of clinical pharmacology. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_F5C6318349C9]
 
The Anti-Malarial Drug Artesunate Attenuates Cardiac Injury in a Rodent Model of Myocardial Infarction.
Khan A.I., Kapoor A., Che J., Martin L., Rogazzo M., Mercier T., Decosterd L., Collino M., Thiemermann C. Shock. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_5C59BA71F335]
 
Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome.
Previsdomini M., Graziano E., Decosterd L., Courlet P., Perren A., Ceschi A. British journal of clinical pharmacology. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_BCDF174FFE06]
 
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Pérez Marín M., Decosterd L.A., Andre P., Buclin T., Mercier T., Murray K., Rizzi M., Meylan P., Jaton-Ogay P., Opota O. et al., 2019/06/11. Journal of the Pediatric Infectious Diseases Society. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_34AA25DDD16D]
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi M., Mercier T., Aouri M., Decosterd L.A., Csajka C., Ogutu B., Carn G., Kiechel J.R., 2019/04/18. Malaria journal, 18 (1) p. 139. Peer-reviewed.
 
Isavuconazole brain penetration in cerebral aspergillosis.
Lamoth F., Mercier T., André P., Pagani J.L., Pantet O., Maduri R., Guery B., Decosterd L.A., 2019/02/11. The Journal of antimicrobial chemotherapy pp. 73-97. Peer-reviewed.
 
Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer A.B., Decosterd L., Osthoff M., Mueller N.J., Buclin T., Corti N., 2019/02. Antimicrobial agents and chemotherapy, 63 (2). Peer-reviewed.
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Sottas O., Guidi M., Thieffry B., Schneider M., Décosterd L., Mueller I., Genton B., Csajka C., Senn N., 2019. PloS one, 14 (2) pp. e0210789. Peer-reviewed.
 
Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
Spaggiari D., Desfontaine V., Cruchon S., Guinchard S., Vocat A., Blattes E., Pitteloud J., Ciullini L., Bardinet C., Ivanyuk A. et al., 2019. PloS one, 14 (5) pp. e0217139. Peer-reviewed.
[DOI] [WoS] [Pmid] [serval:BIB_7C866ED75CDD]
 
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Aicua-Rapun I., André P., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2019/01. Epilepsy research, 149 pp. 88-91. Peer-reviewed.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
 
Levetiracetam circulating concentrations and response in status epilepticus.
Perrenoud M., André P., Buclin T., Decosterd L.A., Rossetti A.O., Novy J., 2018/11. Epilepsy & behavior, 88 pp. 61-65. Peer-reviewed.
 
High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
Tyagi R.K., Gleeson P.J., Arnold L., Tahar R., Prieur E., Decosterd L., Pérignon J.L., Olliaro P., Druilhe P., 2018/10/01. BMC medicine, 16 (1) p. 181. Peer-reviewed.
 
Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring.
Tenaglia E., Ferretti A., Decosterd L.A., Werner D., Mercier T., Widmer N., Buclin T., Guiducci C., 2018/09/10. Journal of pharmaceutical and biomedical analysis, 159 pp. 341-347. Peer-reviewed.
 
Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.
Voumard R., Gardiol C., André P., Arensdorff L., Cochet C., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2018/09/01. The Journal of antimicrobial chemotherapy, 73 (9) pp. 2540-2545. Peer-reviewed.
Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.
Sculier D., Doco-Lecompte T., Yerly S., Metzner K.J., Decosterd L.A., Calmy A., 2018/06/22. HIV medicine, 19 (8) pp. 572-577. Peer-reviewed.
 
The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction.
Khan A.I., Kapoor A., Chen J., Martin L., Rogazzo M., Mercier T., Decosterd L., Collino M., Thiemermann C., 2018/06. Shock, 49 (6) pp. 675-681. Peer-reviewed.
 
LC-MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation.
Gallay J., Prod'hom S., Mercier T., Bardinet C., Spaggiari D., Pothin E., Buclin T., Genton B., Decosterd L.A., 2018/05/30. Journal of pharmaceutical and biomedical analysis, 154 pp. 263-277. Peer-reviewed.
Appropriateness of malaria diagnosis and treatment for fever episodes according to patient history and anti-malarial blood measurement: a cross-sectional survey from Tanzania.
Gallay J., Mosha D., Lutahakana E., Mazuguni F., Zuakulu M., Decosterd L.A., Genton B., Pothin E., 2018/05/21. Malaria journal, 17 (1) p. 209. Peer-reviewed.
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
<i>In vitro</i> study of new combinations for local antibiotic therapy with calcium sulphate - Near constant release of ceftriaxone offers new treatment options.
Wahl P., Rönn K., Bohner M., Decosterd L.A., Meier C., Schläppi M., Festa S., Gautier E., 2018. Journal of bone and joint infection, 3 (4) pp. 212-221. Peer-reviewed.
Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An <i>in Vivo</i> Study With an Experimental Model of Foreign-Body Infection.
Ruppen C., Mercier T., Grandgirard D., Leib S.L., El Haj C., Murillo O., Decosterd L., Sendi P., 2018. Frontiers in microbiology, 9 p. 919. Peer-reviewed.
 
Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania.
Gallay J., Pothin E., Mosha D., Lutahakana E., Mazuguni F., Zuakulu M., Decosterd L.A., Genton B., 2018. PloS one, 13 (9) pp. e0202745. Peer-reviewed.
Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy.
Gayi E., Neff L.A., Massana Muñoz X., Ismail H.M., Sierra M., Mercier T., Décosterd L.A., Laporte J., Cowling B.S., Dorchies O.M. et al., 2018. Nature Communications, 9 (1) p. 4848. Peer-reviewed.
 
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Marzolini C., Decosterd L., Winterfeld U., Tissot F., Francini K., Buclin T., Livio F., 2017/12. British journal of clinical pharmacology, 83 (12) pp. 2835-2838. Peer-reviewed.
Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps.
Arensdorff L., Boillat-Blanco N., Decosterd L., Buclin T., de Vallière S., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2613-2615. Peer-reviewed.
 
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Bartels H., Decosterd L., Battegay M., Marzolini C., 2017/09/01. The Journal of antimicrobial chemotherapy, 72 (9) pp. 2574-2577. Peer-reviewed.
 
Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?
D'Anto J., Wnuk W., Rossetti A.O., Decosterd L.A., Buclin T., Novy J., 2017/09. Epilepsy & behavior, 74 pp. 41-44. Peer-reviewed.
Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement.
Samara E., Moriarty T.F., Decosterd L.A., Richards R.G., Gautier E., Wahl P., 2017/05. Bone & joint research, 6 (5) pp. 296-306. Peer-reviewed.
Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT).
Voumard R., Van Neyghem N., Cochet C., Gardiol C., Decosterd L., Buclin T., de Valliere S., 2017/05/01. The Journal of antimicrobial chemotherapy, 72 (5) pp. 1462-1465. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
 
Is gentamicin necessary in the antimicrobial treatment for group B streptococcal infections in the elderly? An in vitro study with human blood products.
Ruppen C., Decosterd L., Sendi P., 2017/03. Infectious diseases, 49 (3) pp. 185-192. Peer-reviewed.
 
Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Perrenoud M., André P., Alvarez V., Stähli C., Decosterd L.A., Rossetti A.O., Novy J., 2017. Epilepsy Research, 135 pp. 38-42. Peer-reviewed.
 
The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine
Decosterd L.A., Widmer N., André P., Aouri M., Buclin T., 2016/11. TrAC Trends in Analytical Chemistry, 84 pp. 5-13. Peer-reviewed.
 
Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.
Bize P., Duran R., Fuchs K., Dormond O., Namur J., Decosterd L.A., Jordan O., Doelker E., Denys A., 2016/08. Radiology, 280 (2) pp. 425-435. Peer-reviewed.
 
Privacy-preserving genomic testing in the clinic: a model using HIV treatment.
McLaren P.J., Raisaro J.L., Aouri M., Rotger M., Ayday E., Bartha I., Delgado M.B., Vallet Y., Günthard H.F., Cavassini M. et al., 2016/08. Genetics in medicine, 18 (8) pp. 814-822. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
An inhibitor of HIV-1 protease modulates constitutive eIF2α dephosphorylation to trigger a specific integrated stress response.
De Gassart A., Bujisic B., Zaffalon L., Decosterd L.A., Di Micco A., Frera G., Tallant R., Martinon F., 2016. Proceedings of the National Academy of Sciences of the United States of America, 113 (2) pp. E117-E126.
Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.
Hodgson S.H., Llewellyn D., Silk S.E., Milne K.H., Elias S.C., Miura K., Kamuyu G., Juma E.A., Magiri C., Muia A. et al., 2016. Frontiers in microbiology, 7 p. 1604. Peer-reviewed.
 
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M., Barcelo C., Ternon B., Cavassini M., Anagnostopoulos A., Yerly S., Hugues H., Vernazza P., Günthard H.F., Buclin T. et al., 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 44 (1) pp. 151-161.
Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study.
Ruppen C., Lupo A., Decosterd L., Sendi P., 2016. Frontiers in microbiology, 7 p. 1680. Peer-reviewed.
 
Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on Daphnia pulex.
Borgatta M., Waridel P., Decosterd L.A., Buclin T., Chèvre N., 2016. Science of the Total Environment, 545-546 pp. 21-29.
 
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Vionnet J., Saouli A.C., Pascual M., Stucker F., Decosterd L.A., Moradpour D., Chtioui H., 2016. Journal of Hepatology, 65 (5) pp. 1063-1065. Peer-reviewed.
 
Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication.
Kissling S., Fuchs A., Gobin N., Vogt B., Burnier M., Decosterd L.A., Buclin T., Livio F., 2015/11. International Journal of Antimicrobial Agents, 45 (3) pp. 325-327. Peer-reviewed.
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
 
Multiplex Mass Spectrometry Analysis of Latest-Generation Antiepileptic Drugs: A Clinically Useful Laboratory Tool for Improved Real-Time Patients' Care.
Decosterd LA, Mercier T, André P, Bertholet S, Rothuizen LE, Rossetti AO, Buclin T, 2015/06. Epileptologie, 32 (2) pp. 85-89.
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Müllhaupt B., Metzner K.J., Decosterd L. et al., 2015. Plos One, 10 (7) pp. e0133028. Peer-reviewed.
 
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E., Buclin T., Guidi M., Quoix E., Gourieux B., Decosterd L.A., Gairard-Dory A.C., Ubeaud-Séquier G., Widmer N., 2015. Therapeutic Drug Monitoring, 37 (1) pp. 2-21. Peer-reviewed.
 
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A., Eggimann P., Pagani J.L., Revelly J.P., Decosterd L.A., Marchetti O., Pannatier A., Voirol P., Que Y.A., 2015. Burns, 41 (5) pp. 956-968. Peer-reviewed.
 
Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.
Cappi G., Spiga F.M., Moncada Y., Ferretti A., Beyeler M., Bianchessi M., Decosterd L., Buclin T., Guiducci C., 2015. Analytical Chemistry, 87 (10) pp. 5278-5285.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
 
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Schaerer V., Haubitz S., Kovari H., Ledergerber B., Ambrosioni J., Cavassini M., Stoeckle M., Schmid P., Decosterd L., Aouri M. et al., 2015. HIV Medicine, 16 (10) pp. 599-607. Peer-reviewed.
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Vionnet J., Pascual M., Chtioui H., Giostra E., Majno P.E., Decosterd L.A., Moradpour D., 2015. BMC Gastroenterology, 15 (1) p. 38. Peer-reviewed.
 
The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study.
Borgatta M., Decosterd L.A., Waridel P., Buclin T., Chèvre N., 2015. Science of the Total Environment, 520 pp. 232-240.
 
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century
André P., Novy J., Decosterd LA, Buclin T., Rothuizen LE, 2015/01/01. Epileptologie 32 pp. 78-84.
 
Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities.
Wang X., Gronchi F., Bensimon M., Mercier T., Decosterd L.A., Wagnières G., Debefve E., Ris H.B., Letovanec I., Peters S. et al., 2015. Lasers In Surgery and Medicine, 47 (10) pp. 807-816. Peer-reviewed.
 
A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry, microarray and PCR.
Vogne C., Prod'hom G., Jaton K., Decosterd L.A., Greub G., 2014. Clinical Microbiology and Infection, 20 (12) pp. O1106-O1112. Peer-reviewed.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model.
Perentes J.Y., Wang Y., Wang X., Abdelnour E., Gonzalez M., Decosterd L., Wagnieres G., van den Bergh H., Peters S., Ris H.B. et al., 2014. Translational Oncology, 7 (3) pp. 393-399. Peer-reviewed.
 
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
 
Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
Dahmane E., Boccard J., Csajka C., Rudaz S., Décosterd L., Genin E., Duretz B., Bromirski M., Zaman K., Testa B. et al., 2014. Analytical and Bioanalytical Chemistry, 406 (11) pp. 2627-2640. Peer-reviewed.
 
Shotgun Ecotoxicoproteomics of Daphnia pulex: Biochemical Effects of the Anticancer Drug Tamoxifen.
Borgatta M., Hernandez C., Decosterd L.A., Chèvre N., Waridel P., 2014. Journal of Proteome Research, 14 (1) pp. 279-291.
 
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
Makarov V., Lechartier B., Zhang M., Neres J., van der Sar A.M., Raadsen S.A., Hartkoorn R.C., Ryabova O.B., Vocat A., Decosterd L.A. et al., 2014. Embo Molecular Medicine, 6 (3) pp. 372-383. Peer-reviewed.
Intravenous streptomycin dosing regimen in a patient undergoing hemodialysis: Plasma level monitoring and pharmacokinetic simulation
Chtioui H., Zbinden D., Manuel O., Entenza J., Decosterd L.A., Buclin T., 2013/08. pp. e106 dans 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, Clinical Therapeutics.
 
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M., Calmy A., Hirschel B., Telenti A., Buclin T., Cavassini M., Rauch A., Decosterd L.A., 2013. Journal of Mass Spectrometry, 48 (5) pp. 616-625.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from the randomized controlled I-COME Trial
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Benz R., Gregor M., Leoncini-Franscini L., Baerlocher G., Duchosal M. et al., 2013. pp. e6 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Efavirenz intoxication due to a new CYP2B6 constellation.
Anagnostopoulos A., Rotger M., Aouri M., Kuster S.P., Telenti A., Décosterd L.A., Günthard H.F., 2013. Antiviral Therapy, 18 (5) pp. 739-743.
 
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.
Staehli Hodel E.M., Csajka C., Ariey F., Guidi M., Kabanywanyi A.M., Duong S., Decosterd L.A., Olliaro P., Beck H.P., Genton B., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 950-958.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
 
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A., Vernazza P.L., Yerly S., Decosterd L.A., Ledergerber B., Fux C.A., Rohrbach J., Widmer N., Hirschel B., Gaudenz R. et al., 2013. Journal of Acquired Immune Deficiency Syndromes, 62 (1) pp. 28-35. Peer-reviewed.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
 
The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.
Dorchies O.M., Reutenauer-Patte J., Dahmane E., Ismail H.M., Petermann O., Patthey- Vuadens O., Comyn S.A., Gayi E., Piacenza T., Handa R.J. et al., 2013. American Journal of Pathology, 182 (2) pp. 485-504.
 
A highly sensitive LC-tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers.
Sidler-Moix A.L., Mercier T., Decosterd L.A., Di Paolo E.R., Berger-Gryllaki M., Cotting J., Pannatier A., 2012. Biomedical Chromatography : BMC, 26 (5) pp. 672-680. Peer-reviewed.
 
Antimicrobial Agents
Csajka C., Marchetti O., Manuel O., Decosterd L., Telenti A., 2012. pp. 379-402 dans Anzenbacher P., Zanger U.M. (eds.) Metabolism of Drugs and Other Xenobiotics chap. 14, Wiley-VCH Verlag.
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H.C., Günthard H.F., Rickenbach M., Nicca D., Hirschel B. et al., 2012/01. Plos One, 7 (1) pp. e29186. Peer-reviewed.
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
 
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Aouri M., Decosterd L.A., Buclin T., Hirschel B., Calmy A., Livio F., 2012. AIDS, 26 (6) pp. 776-778.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Inhibiteurs des tyrosines kinases dans la LMC: Guide pratique des interactions médicamenteuses
Widmer N., Decosterd L.A., Nicolini F., Rothuizen L., Réa D., 2012., 2012 80, Editions Scientifiques L & C.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
 
Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density.
Wang Y., Gonzalez M., Cheng C., Haouala A., Krueger T., Peters S., Decosterd L.A., van den Bergh H., Perentes J.Y., Ris H.B. et al., 2012. Lasers in Surgery and Medicine, 44 (4) pp. 318-324. Peer-reviewed.
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
 
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M., 2011. Journal of Antimicrobial Chemotherapy, 66 (7) pp. 1573-1581.
 
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A., 2011. Blood, 117 (8) pp. e75-e87. Peer-reviewed.
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
Magenta L., Dell-Kuster S., Richter W.O., Young J., Hasse B., Flepp M., Hirschel B., Vernazza P., Evison J., Cavassini M. et al., 2011. Aids Research and Human Retroviruses, 27 (5) pp. 525-533.
 
P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.
Kuemmerle A., Yan H., Krueger T., Buclin T., Braissant O., Henry H., Ris H.B., Decosterd L.A., 2011. Anticancer Research, 31 (6) pp. 2121-2128.
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
 
Photodynamic therapy enhances liposomal doxorubicin distribution in tumors during isolated perfusion of rodent lungs.
Cheng C., Wang Y., Haouala A., Debefve E., Andrejevic Blant S., Krueger T., Gonzalez M., Ballini J.P., Peters S., Decosterd L. et al., 2011. European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes, 47 (4) pp. 196-204.
 
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Fayet Mello A., Buclin T., Decosterd L.A., Delhumeau C., di Iulio J., Fleurent A., Schneider M.P., Cavassini M., Telenti A., Hirschel B. et al., 2011. Antiviral Therapy, 16 (2) pp. 189-197.
 
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T., Widmer N., Biollaz J., Decosterd L.A., 2011. Lancet Oncology, 12 (1) pp. 9-11. Peer-reviewed.
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
 
Cardiovascular drug interactions with tyrosine kinase inhibitors
Haouala A., Widmer N., Montemurro M., Buclin T., Decosterd L., 2010. Cardiovascular Medicine, 13 (5) pp. 147-154. Peer-reviewed.
 
Determination of oseltamivir and oseltamivir carboxylate in human plasma by liquid chromatography-tandem mass spectrometry
Aouri M., Zanolari B., Meylan P., Ivanyuk A., Buclin T., Decosterd L.A., Widmer N., 2010. pp. 25S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Ganciclovir exposure under a 450mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical Transplantation, 24 (6) pp. 794-800.
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
 
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
Scherrer A.U., von Wyl V., Fux C.A., Opravil M., Bucher H.C., Fayet A., Decosterd L.A., Hirschel B., Khanlari B., Yerly S. et al., 2010. Journal of Acquired Immune Deficiency Syndromes, 53 (4) pp. 464-471.
 
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.
Decosterd L.A., Rochat B., Pesse B., Mercier T., Tissot F., Widmer N., Bille J., Calandra T., Zanolari B., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5303-5315. Peer-reviewed.
 
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N., Meylan P., Ivanyuk A., Aouri M., Decosterd L.A., Buclin T., 2010. Clinical Pharmacokinetics, 49 (11) pp. 741-765. Peer-reviewed.
 
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
Neely Michael, Decosterd Laurent, Fayet Aurelie, Lee Janice Soo Fern, Margol Ashley, Kanani Meera, di Iulio Julia, von Schoen-Angerer Tido, Jelliffe Roger, Calmy Alexandra, 2010. Antimicrobial Agents and Chemotherapy, 54 (11) pp. 4619-4625.
 
Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs.
Cheng C., Debefve E., Haouala A., Andrejevic-Blant S., Krueger T., Ballini J.P., Peters S., Decosterd L., van den Bergh H., Wagnieres G. et al., 2010. Lasers in Surgery and Medicine, 42 (5) pp. 391-399.
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
Prospective monitoring of cefepime in intensive care unit adult patients.
Chapuis T.M., Giannoni E., Majcherczyk P.A., Chioléro R., Schaller M.D., Berger M.M., Bolay S., Décosterd L.A., Bugnon D., Moreillon P., 2010. Critical Care, 14 (2) pp. R51.
 
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
Gutmann C., Cusini A., Günthard H.F., Fux C., Hirschel B., Decosterd L.A., Cavassini M., Yerly S., Vernazza P.L., Swiss HIV Cohort Study (SHCS), 2010. Aids, 24 (15) pp. 2347-2354.
 
Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.
Hodel Eva Maria, Genton Blaise, Zanolari Boris, Mercier Thomas, Duong Socheat, Beck Hans-Peter, Olliaro Piero, Decosterd Laurent A., Ariey Frederic, 2010. Journal of Infectious Diseases, 202 (7) pp. 1088-1094.
 
siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors.
Haouala A., Rumpold H., Untergasser G., Buclin T., Ris H.B., Widmer N., Decosterd L.A., 2010. Drug Metabolism Letters, 4 (2) pp. 114-119. Peer-reviewed.
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
Widmer N., Gotta V., Haouala A., Decosterd L.A., 2010. Leukemia Research, 34 (6) pp. 698-699. Peer-reviewed.
 
Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.
Rochat B., Pascual A., Pesse B., Lamoth F., Sanglard D., Decosterd L.A., Bille J., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5074-5081.
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet Nancy, Manuel Oriol, Lamoth Frederic, Venetz Jean-Pierre, Sahli Roland, Decosterd Laurent A., Buclin Thierry, Pascual Manuel, Meylan Pascal, 2010. BMC Infectious Diseases, 10 p. 2.
Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
Hodel E.M., Kabanywanyi A.M., Malila A., Zanolari B., Mercier T., Beck H.P., Buclin T., Olliaro P., Decosterd L.A., Genton B., 2009/12/14. PloS one, 4 (12) pp. e8184. Peer-reviewed.
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
 
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Kuemmerle A., Decosterd L. A., Buclin T., Liénard D., Stupp R., Chassot P. G., Mosimann F., Lejeune F., 2009. Cancer Chemotherapy and Pharmacology, 63 (2) pp. 331-341. Peer-reviewed.
 
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
Hodel Eva Maria, Zanolari Boris, Mercier Thomas, Biollaz Jérôme, Keiser J., Olliaro P., Genton B., Decosterd Lurent-Arthur, 2009. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 877 (10) pp. 867-886.
 
Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin.
Cheng C., Haouala A., Krueger T., Mithieux F., Perentes J.Y., Peters S., Decosterd L.A., Ris H.B., 2009. Interactive Cardiovascular and Thoracic Surgery, 8 (6) pp. 635-638.
 
Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplant recipients: a prospective study : P125
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L., Buclin T., Meylan P., 2009. pp. 32S-33S dans Joint Annual Congress of the Swiss Society for Allergology and Immunology and the Swiss Society for Infectious Diseases, Swiss Medical Weekly. Peer-reviewed.
 
Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.
Manuel Oriol, Pascual Manuel, Perrottet Nancy, Lamoth Frederic, Venetz Jean-Pierre, Decosterd Laurent, Buclin Thierry, Meylan Pascal R., 2009. p. 249 dans 9th Joint Meeting of the American Society of Transplant Surgeon and of the American Society of Transplantation, American Journal of Transplantation. Peer-reviewed.
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
 
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica
Keiser Jennifer, Gruyer Marie-Stella, Perrottet Nancy, Zanolari Boris, Mercier Thomas, Decosterd Laurent, 2009. Journal of Antimicrobial Chemotherapy, 63 (3) pp. 543-549. Peer-reviewed.
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
 
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A., 2009. Journal of Chromatography. B, 877 (22) pp. 1982-1996. Peer-reviewed.
 
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T., 2009. Clinical Pharmacokinetics, 48 (6) pp. 399-418. Peer-reviewed.
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008/07/16. Revue medicale suisse, 4 (165) pp. 1644-1648. Peer-reviewed.
[Pmid] [serval:BIB_3645892D4B54]
 
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
Rochat B., Fayet A., Widmer N., Lahrichi S.L., Pesse B., Décosterd L.A., Biollaz J., 2008/02. Journal of mass spectrometry, 43 (6) pp. 736-52. Peer-reviewed.
 
Disposition of oral valganciclovir during continuous renal replacement therapy in two lung transplant recipients
Perrottet Nancy, Robatel Corinne, Meylan Pascal, Pascual Manuel, Venetz Jean-Pierre, Aubert John-David, Berger Mette M., Decosterd Laurent A., Biollaz Jerome, Buclin Thierry, 2008. p. 566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
 
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
Perrottet N., Robatel C., Meylan P., Pascual M., Venetz J.P., Aubert J.D., Berger M.M., Decosterd L.A., Buclin T., 2008. Journal of Antimicrobial Chemotherapy, 61 (6) pp. 1332-1335.
 
Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model.
Yan H., Cheng C., Haouala A., Krueger T., Ballini J.P., Peters S., Decosterd L.A., Letovanec I., Ris H.B., Andrejevic-Blant S., 2008. Annals of Thoracic Surgery, 85 (4) pp. 1225-1232.
 
Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Csajka C., Cavassini M., Rotger M., Decosterd L. A., Furrer H., Calmy A., Fayet A., Arab-Alameddine M., Widmer N., di Iulio J. et al., 2008. Pharmacotherapy, 28 (9) pp. 215e-216e. Peer-reviewed.
 
Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
Perrottet Nancy, Manuel Oriol, Venetz Jean-Pierre, Lamoth Frederic, Decosterd Laurent A., Buclin Thierry, Biollaz Jerome, Meylan Pascal, Pascual Manuel, 2008. pp. 565-566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
 
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Rotger M., Saumoy M., Zhang K., Flepp M., Sahli R., Decosterd L., Telenti A., 2007/10. Pharmacogenetics and Genomics, 17 (10) pp. 885-90.
 
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., Biollaz J., Decosterd L. A., 2007/06. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 852 (1-2) pp. 420-9.
 
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial
Vernazza P., Daneel S., Schiffer V., Decosterd L., Fierz W., Klimkait T., Hoffmann M., Hirschel B., 2007/06. AIDS, 21 (10) pp. 1309-15.
 
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Decosterd L., Blievernicht J., Saussele T., Gunthard H. F., Schwab M. et al., 2007/04. Clinical Pharmacology and Therapeutics, 81 (4) pp. 557-66.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Does tenofovir influence efavirenz pharmacokinetics?
Rotger M., Colombo S., Furrer H., Decosterd L., Buclin T., Telenti A., 2007. Antiviral Therapy, 12 (1) pp. 115-8.
 
Effect of dronedarone on renal function in healthy subjects.
Tschuppert Y., Buclin T., Rothuizen L.E., Decosterd L.A., Galleyrand J., Gaud C., Biollaz J., 2007. British Journal of Clinical Pharmacology, 64 (6) pp. 785-791. Peer-reviewed.
 
Pharmacokinetic and pharmacodynamic assessement of valganciclovir in the prophylaxis and treatment of CMV disease in solid organ transplant patients
Manuel O., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2007. pp. 9S dans Annual Conference Swiss Society for Paediatrics, Swiss Medical Weekly. Peer-reviewed.
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.
Widmer N., Rumpold H., Untergasser G., Fayet A., Buclin T., Decosterd L.A., 2007. Leukemia, 21 (7) pp. 1561-2; author reply 1562-4. Peer-reviewed.
 
Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2'-deoxy-(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro
Coucke P. A., Cottin E., Decosterd L. A., 2007. Acta Oncologica, 46 (5) pp. 612-20.
 
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., Marchetti O., 2007. Antimicrobial Agents and Chemotherapy, 51 (1) pp. 137-143.
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
 
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S., Telenti A., Buclin T., Furrer H., Lee B. L., Biollaz J., Decosterd L. A., 2006/06. Therapeutic Drug Monitoring, 28 (3) pp. 332-8.
 
Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., Hug C., Pilet M., Roulet M., 2006/06. Clinical Nutrition, 25 (3) pp. 418-427. Peer-reviewed.
 
Pharmacogenetics
Lee-Tauber Belle, Decosterd Laurent A., Korb Reinhold, Telenti Amalio, 2006/05/16. pp. 155-187 dans Pharmacogenetics in infectious diseases chap. 9, Ian P Hall, Munir Pirohamed.
[serval:BIB_433B26A29F8B]
 
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.
Colombo S., Béguin A., Marzolini C., Telenti A., Biollaz J., Decosterd L.A., 2006/02. Journal of Chromatography. B, 832 (1) pp. 138-143. Peer-reviewed.
 
Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model.
Krueger T., Kuemmerle A., Andrejevic-Blant S., Yan H., Pan Y., Ballini J.P., Klepetko W., Decosterd L.A., Stupp R., Ris H.B., 2006. Annals of Thoracic Surgery, 82 (6) pp. 2024-2030.
 
Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: evaluation of different cytostatic lung perfusion techniques in a porcine model.
Krueger T., Kuemmerle A., Kosinski M., Denys A., Magnusson L., Stupp R., Delaloye A.B., Klepetko W., Decosterd L., Ris H.B. et al., 2006. Journal of Thoracic and Cardiovascular Surgery, 132 (2) pp. 304-311.
 
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
Neef M., Ledermann M., Saegesser H., Schneider V., Widmer N., Decosterd L. A., Rochat B., Reichen J., 2006/01. Journal of Hepatology, 44 (1) pp. 167-75. Peer-reviewed.
 
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S., Buclin T., Décosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., Eap C.B. and , 2006. Clinical pharmacology and therapeutics, 80 (4) pp. 307-18. Peer-reviewed.
 
Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients
Manuel O., Perrottet N., Venetz J.P., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2006. pp. S19 dans 12th International Society for infectious Diseases, International Journal of Infectious Diseases. Peer-reviewed.
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
 
Prospective determination of plasma imipenem concentrations in critically ill children.
Giannoni E., Moreillon P., Cotting J., Moessinger A., Bille J., Décosterd L., Zanetti G., Majcherczyk P., Bugnon D., 2006. Antimicrobial Agents and Chemotherapy, 50 (7) pp. 2563-2568.
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
Colombo S., Buclin T., Franc C., Guignard N., Khonkarly M., Tarr P. E., Rochat B., Biollaz J., Telenti A., Decosterd L. A. et al., 2006. Antiviral Therapy, 11 (1) pp. 53-62.
 
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
Colombo S., Soranzo N., Rotger M., Sprenger R., Bleiber G., Furrer H., Buclin T., Goldstein D., Decosterd L., Telenti A., 2005/09. Pharmacogenetics and Genomics, 15 (9) pp. 599-608.
 
A validated liquid chromatography-mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes
Panchaud A., Avois L., Roulet M., Pilet M., Hug C., Saugy M., Decosterd L. A., 2005/06. Analytical Biochemistry, 341 (1) pp. 58-68.
 
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L. A., 2005/05. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 819 (2) pp. 259-76.
 
Dietary supplementation with omega-3 in cystic fibrosis patients
Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Hug C., Pilet M., Roulet M., 2005. pp. S88 dans 28th European Cystic Fibrosis Conference, Journal of Cystic Fibrosis. Peer-reviewed.
 
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B. L., Keiser O., Biollaz J., Decosterd L., Telenti A., 2005/01. Pharmacogenetics and Genomics, 15 (1) pp. 1-5.
 
Pharmacologie et toxicologie: le suivi thérapeutique des médicaments - vers un pilotage précis des traitements
Buclin T., Decosterd L.A., 2005. Swiss Medical Forum = Forum Médical Suisse, 5 (51-52) pp. 1301-1303.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
Gambillara E., Laffitte E., Widmer N., Decosterd L. A., Duchosal M. A., Kovacsovics T., Panizzon R. G., 2005. Dermatology, 211 (4) pp. 363-365. Peer-reviewed.
 
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.
Fellay J., Marzolini C., Decosterd L., Golay K.P., Baumann P., Buclin T., Telenti A., Eap C.B., 2005. European journal of clinical pharmacology, 60 (12) pp. 865-73. Peer-reviewed.
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction
Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L. A., 2004/10. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 810 (1) pp. 25-34.
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka C., Marzolini C., Fattinger K., Decosterd L. A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial Agents and Chemotherapy, 48 (9) pp. 3226-32.
 
Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine
Coucke P. A., Cottin E., Azria D., Martineau P., Adamer F., Decosterd L. A., Buchegger F., Do H. P., 2004/07. European Journal of Cancer, 40 (10) pp. 1572-1580.
 
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L. A., Stupp R., 2004/06. Clinical Cancer Research, 10 (11) pp. 3728-36.
 
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Widmer N., Beguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M. A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. A., 2004/04. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 803 (2) pp. 285-292. Peer-reviewed.
 
Dose-adjustment of imatinib based on plasma level measurement in a patient with CML
Heizmann M., Widmer N., Decosterd L.A., Oppliger E., Tobler A., 2004. pp. 32S dans 72e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Dose-adjustment of imatinib based on plasma level measurement in a patient with CML
Heizmann M., Widmer N., Decosterd L.A., Oppliger E., Tobler A., 2004. pp. S39 dans 9th Congress of the European Hematology Association (EHA), Hematology Journal. Peer-reviewed.
 
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
Robatel C., Decosterd L. A., Biollaz J., Eckert P., Schaller M. D., Buclin T., 2003/12. Journal of Clinical Pharmacology, 43 (12) pp. 1329-40.
 
Functional consequence of MDR1 expression on imatinib intracellular concentrations
Widmer N., Colombo S., Buclin T., Decosterd L. A., 2003/08. Blood, 102 (3) p. 1142. Peer-reviewed.
 
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days
Vouillamoz-Lorenz S., Buclin T., Lejeune F., Bauer J., Leyvraz S., Decosterd L. A., 2003/06. Anticancer Research, 23 (3C) pp. 2757-65.
 
A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements.
Kümmerle A., Krueger T., Dusmet M., Vallet C., Pan Y., Ris H.B., Decosterd L.A., 2003. Journal of Pharmaceutical and Biomedical Analysis, 33 (3) pp. 475-494. Peer-reviewed.
 
NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios
Nyeki A., Buclin T., Biollaz J., Decosterd L. A., 2003/01. British Journal of Clinical Pharmacology, 55 (1) pp. 62-7.
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
 
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery
Marzolini C., Beguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., Decosterd L. A., 2002/07. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 774 (2) pp. 127-40.
 
Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
Robatel C., Buclin T., Eckert P., Schaller M.D., Biollaz J., Decosterd L.A., 2002. Journal of pharmaceutical and biomedical analysis, 29 (1-2) pp. 17-33. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University